Methods of optimizing antibody variable region binding affinity

Details Methods of optimizing antibody variable region binding affinity Methods of optimizing antibody variable region binding affinity

2005-02-01

2005-02-01

Helms, Larry R. (Department: 1642)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S069600, C530S387300

Reexamination Certificate

active

06849425

ABSTRACT:
The invention provides a method of conferring donor CDR binding affinity onto an antibody acceptor variable region framework. The invention also provides a method of simultaneously grafting and optimizing the binding affinity of a variable region binding fragment. A method of optimizing the binding affinity of an antibody variable region is also provided.

REFERENCES:
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5264563 (1993-11-01), Huse
patent: 5585089 (1996-12-01), Queen et al.
patent: 5589573 (1996-12-01), Hagiwara et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5723323 (1998-03-01), Kauffman et al.
patent: 5814476 (1998-09-01), Kauffman et al.
patent: 5817483 (1998-10-01), Kauffman et al.
patent: 5824514 (1998-10-01), Kauffman et al.
patent: 5976862 (1999-11-01), Kauffman et al.
patent: 5977322 (1999-11-01), Marks et al.
patent: 6096551 (2000-08-01), Barbas et al.
patent: 6312693 (2001-11-01), Aruffo et al.
patent: 2125240 (1995-12-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0 519 596 (1992-05-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0 939 127 (1999-09-01), None
patent: WO 9942075 (1999-08-01), None
Yelton et al., The Journal of Immunology 155:1994-2004, 1995.*
Boca et al., The Journal of Biological Chemistry 272:10678-84, Apr. 1997.*
Baca et al., Proc. Natl. Acad. Sci. USA 94:10063-10068, Sep. 1997.*
Amit et al., Science 233:747-753, 1986.*
Rudikoff et al., Proc. Natl. Acad. Sci. USA 79:1979, 1982.*
Baca et al., “Phage display of a catalytic antibody to optimize affinity for transition-state analog binding,” Proc. Natl. Acad. Sci. USA, 94:10063-10068 (1997).
Irving et al., “Affinity maturation of recombinant antibodies using E. coli mutator cells,” Immunotechnology, 2:127-143 (1996).
Chothia and Lesk, “Canonical structures for the hypervariable regions of immunoglobulins,”J. Mol. Biol.196:901-917 (1987).
Chothia et al., “Conformations of immunoglobulin hypervariable regions,”Nature342:877-883 (1989).
Foote and Winter, “Antibody framework residues affecting the conformation of the hypervariable loops,”J. Mol. Biol.224:487-499 (1992).
Glaser et al., “Antibody engineering by codon-based mutagenesis in a filamentous phage vector system,”J. Immunology149:3903-3913 (1992).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature321:522-525 (1986).
Kabat et al., “Unusual distributions of amino acids in complementarity-determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites,”J. Biol. Chem.252:6609-6616 (1977).
Kabat et al., “Sequences of proteins of immunological interest,” (5thEd) Washington DC: United States Department of Health and Human Services (1991). Introduction + References to Introduction.
Kristensson et al., “Humanization of a murine antibody againstcryptococcus neoformanspolysaccharide using a novel approach,”Vaccines 95, 39-43 Cold Spring Habor Laboratory Press, Cold Sprign Harbor, NY (1995).
MacCallumm et al., “Antibody-antigen interactions: contact analysis and binding site topography,”J. Mol. Biol.262:732-745 (1996).
Padlan, E.A., “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties,”Mol. Immunol.28:489-498 (1991).
Padlan, E.A., “Anatomy of the antibody molecule,”Mol. Immunol.31:169-217 (1994).
Rader et al., “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,”Proc. Natl. Acad. Sci. USA95:8910-8915 (1998).
Riechmann et al., “Reshaping human antibodies for therapy,”Nature332:323-327 (1988).
Rosok et al., “A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab,”J. Biol. Chem.271:22611-22618 (1996).
Schier et al., “Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site,”J. Mol. Biol.263:551-567 (1996).
Schreiber and Fersht, “Energetics of protein-protein interactions: Analysis of the barnase-barstar interface by single mutations and double mutant cycles,”J. Mol. Biol.248:478-486 (1995).
Singer et al., “Optimal humanization of 1B4, an anti-CD 18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences,”J. Immunol.150:2844-2857 (1993).
Studnicka et al., “Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues,”Protein Eng.7:805-814 (1994).
Thompson et al., “Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: Use of phage display to improve affinity and broaden strain reactivity,”J. Mol. Biol.256:77-88 (1996).
Watkins et al., “Determination of the relative affinities of antibody fragments expressed inEscherichia coliby enzyme-linked immunosorbent assay,”Anal. Biochem.253:37-45 (1997).
Watkins et al., “Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antiboty libraries,”Anal. Biochem.256:169-177 (1998).
Wu et al., “Stepwise in vitro affinity maturation of Vitaxin, and αvβ3-specific humanized mAb,”Proc. Natl. Acad. Sci. USA95:6037-6042 (1998).
Yelton et al., “Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis,”J. Immunol.155:1994-2004 (1995).

Affiliated with

Also associated with

Rating

Methods of optimizing antibody variable region binding affinity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of optimizing antibody variable region binding affinity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of optimizing antibody variable region binding affinity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3490445